Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough

“…In this issue of the journal, Lanino et al present realworld data from an Italian luspatercept compassionate use trial for patients with lower risk MDS-RS (R-IPSS-very low, low, and intermediate risk; FISiM study), who were refractory to, or ineligible for ESA therapy and who were RBC-TD (≥2 units of red cells/8 weeks in the last 16 weeks prior to enrollment). 14 Notably, these patients were not T A B L E 1 Clinical trial and real-world data aggregates on the efficacy and safety of luspatercept in congenital and acquired sideroblastic anemias. 17 These effects were particularly pronounced in patients with SF3B1 MT -MDS and MDS-RS.…”